PRECISE: A prognostic thyroid follicular-cell derived gene signature for papillary thyroid carcinoma
Papillary thyroid carcinoma (PTC) exhibits heterogeneous behavior. There is a need for effective biomarkers and improved risk stratification methods in PTC. Gene signatures derived from bulk RNA sequencing capture composite transcriptional profiles that are confounded by tumor microenvironment cells. We developed a thyroid follicular cell–enriched gene signature, Prognostic RNA Expression Cell-specific Integrated SignaturE (PRECISE), using single-cell RNA sequencing techniques and evaluated its prognostic utility across three independent cohorts with bulk RNA-seq data and survival outcomes. Overall design: Primary tumor samples were from surgical resection and analyzed using bulk RNA sequencing.